OptiLeukin^™ 2 – Recombinant human interleukin-2

Product Description

OptiLeukin™ 2 is a high-purity, recombinant human interleukin-2 (rhIL-2) developed for ex vivo immune cell expansion and next-generation biomanufacturing. Free of bacterial and animal components, OptiLeukin 2 eliminates risks associated with endotoxins, host cell proteins, and serum-derived impurities.

Formulated as a lyophilized powder and rigorously tested to ensure batch-to-batch consistency, OptiLeukin 2 delivers reliable performance in T and NK cell expansion, immune activation, and cell therapy applications. Unlike E. coli- or HEK-derived alternatives, OptiLeukin 2 supports safer regulatory submissions with unmatched purity and reproducibility.

With mass-based reconstitution and activity calibrated to the NIBSC 1st International Standard, OptiLeukin-2 is compatible with defined media systems and scalable from R&D to GMP-grade clinical manufacturing.

Advantages

• Optimized for Serum-Free, Animal-Origin-Free Cell Culture
  • Fully recombinant, blood- and bacteria-free IL-2—ensuring consistent performance without endotoxin or host cell protein risk.
  • Produced using a non-animal, non-human, and non-bacterial expression system to support regulatory and clinical compatibility.
  • All raw materials, production equipment, and packaging are free from animal components, supporting high-purity and ethical standards.
• High Potency and Bioactivity
  • OptiLeukin 2 delivers robust IL-2 signaling to drive potent T and NK cell proliferation, viability, and effector function.
  • Activity measured relative to the NIBSC 1st International Standard for IL-2, ensuring consistent performance across research, development, and manufacturing.
  • Supports consistent immune cell activation and expansion, even in serum-free and chemically defined systems—making it ideal for CAR-T, NK-based therapies, and advanced immunotherapy platforms.
• Manufactured in the United States
  • Produced in a tertiary-level, ISO 9001:2015-certified facility in the USA.
  • Complete supply and manufacturing chain is owned and operated by InVitria, ensuring unmatched traceability and quality control.
  • Batch-to-batch consistency for reliable integration into cGMP bioproduction workflows.
• Ready-to-Use Lyophilized Format
  • Reconstitutes easily into chemically defined media at 100–200 µg/mL.
  • Enables consistent cytokine performance without the variability associated with E. coli-derived or plasma-derived IL-2.

Applications

• Cell Therapy & Immunotherapy Development
  • Promotes robust expansion of T cells, Tregs, TILs, γδ T cells, and NK cells for CAR-T, TCR, and innate-like cell therapies.
  • Delivers consistent performance in ex vivo immune cell activation and expansion workflows.
  • Supports defined, serum-free manufacturing of engineered immune cells.
• Bioproduction & Clinical Manufacturing
  • Compatible with GMP-aligned workflows and chemically defined media.
  • Ensures consistent cytokine activity and low variability during scale-up for therapeutic manufacturing.
• Stem Cell-Based Immune Modulation
  • Enables IL-2–driven proliferation in iPSC-derived immune cell lineages.
  • Supports functional differentiation and activation of immune-modulatory cells in regenerative platforms.
  • Chemically defined formulation eliminates variability from serum-derived cytokines.
• Defined Media & Cell Culture Optimization
  • Functions as a reliable IL-2 component in serum-free or xeno-free media formulations.
  • Facilitates reproducibility and regulatory alignment in advanced cell culture systems.
  • Provides a defined, serum-free alternative for cell therapy applications.
  • Optimized for inclusion with other recombinant supplements like Optiferrin and Cellastim S.
• Ex Vivo Expansion of T and NK Cells 
  • Enhances proliferation, cytotoxicity, and viability of T cells, Tregs, TILs, γδ T cells, and NK cells.
  • Essential for clinical-scale immune cell production and downstream therapeutic dosing.
  • Used in conjunction with other interleukins or activation protocols in custom cocktails.

Technical Specifications

• Formulation: Lyophilized recombinant human interleukin-2
• Manufacturing: Produced in a state-of-the-art, ISO 9001:2015-certified, cGMP compliant facility in the USA
• Quality Assurance:
  • Fully recombinant and animal-origin-free production system
  • Stringent quality control processes ensure high batch-to-batch consistency
• Regulatory Compliance & Safety:
  • cGMP-compliant manufacturing
  • Plasma-free, pathogen-free, and chemically defined
  • Aligned with regulatory expectations for biopharmaceutical, regenerative medicine, and vaccine production applications

Why Choose OptiLeukin 2?

OptiLeukin 2 provides a clean, reliable, and scalable IL-2 solution for companies advancing cell therapies and immunotherapies. By removing the risks associated with E. coli and HEK expression systems, it ensures compatibility with regulatory frameworks and supports consistent manufacturing outcomes. Backed by InVitria’s proven record in recombinant protein technology, OptiLeukin 2 empowers innovators to build robust, animal-origin-free workflows—without compromising performance.

See the Terms page for more information about the trademarks and patents covering this product.